Overview Dividends

(HCA) HCA Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40412C1018

Hospitals, Healthcare, Surgery, Emergency, Therapy Centers, Diagnostic Services

HCA EPS (Earnings per Share)

EPS Growth (3Y CAGR): 22.48%
EPS Trend (3Y Correlation): 47.1%

HCA Revenue

Revenue Growth (3Y CAGR): 8.22%
Revenue Trend (3Y Correlation): 97.9%

Description: HCA HCA Holdings

HCA Healthcare, Inc. is a leading healthcare provider in the United States, operating a diverse network of hospitals, outpatient facilities, and other healthcare entities. The companys comprehensive services span general and acute care, including inpatient and outpatient services, diagnostic and emergency care, and specialized therapies.

With a presence in various markets, HCA Healthcare offers a broad range of services, including behavioral health, surgical services, and rehabilitation programs. The companys operational footprint includes general and acute care hospitals, freestanding emergency care facilities, urgent care centers, and various other outpatient facilities. Key performance indicators (KPIs) to watch include same-store sales growth, patient volume, and revenue per patient, which can indicate the companys operational efficiency and market competitiveness.

From a financial perspective, HCA Healthcares revenue growth, operating margins, and return on equity (ROE) are crucial metrics. While the reported ROE of -235.88% is concerning, its essential to analyze the underlying drivers, such as one-time charges or accounting adjustments, to understand the companys true financial health. Other important KPIs include debt-to-equity ratio, interest coverage, and cash flow generation, which can provide insights into the companys capital structure and ability to invest in growth initiatives.

To further evaluate HCA Healthcares prospects, its essential to examine industry trends, competitive positioning, and regulatory factors. The companys market share, geographic diversification, and service line mix can impact its long-term growth and profitability. Additionally, monitoring developments in healthcare policy, reimbursement rates, and technological advancements can help inform investment decisions.

HCA Stock Overview

Market Cap in USD	98,458m
Sub-Industry	Health Care Facilities
IPO / Inception	2011-03-10

HCA Stock Ratings

Growth Rating	66.3%
Fundamental	77.5%
Dividend Rating	54.8%
Return 12m vs S&P 500	-12.4%
Analyst Rating	4.08 of 5

HCA Dividends

Dividend Yield 12m	0.92%
Yield on Cost 5y	2.67%
Annual Growth 5y	27.94%
Payout Consistency	53.8%
Payout Ratio	11.6%

HCA Growth Ratios

Growth Correlation 3m	61.8%
Growth Correlation 12m	26.1%
Growth Correlation 5y	90.2%
CAGR 5y	25.80%
CAGR/Max DD 3y	0.91
CAGR/Mean DD 3y	4.38
Sharpe Ratio 12m	1.64
Alpha	-13.59
Beta	0.882
Volatility	30.91%
Current Volume	761.2k
Average Volume 20d	1081.2k
Stop Loss	392.9 (-3%)
Signal	0.87

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (5.97b TTM) > 0 and > 6% of Revenue (6% = 4.36b TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA 3.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -0.52% (prev 1.28%; Δ -1.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 13.59b > Net Income 5.97b (YES >=105%, WARN >=100%)

Net Debt (45.42b) to EBITDA (14.36b) ratio: 3.16 <= 3.0 (WARN <= 3.5)

Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (241.9m) change vs 12m ago -8.39% (target <= -2.0% for YES)

Gross Margin 15.24% (prev 14.90%; Δ 0.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 124.4% (prev 119.1%; Δ 5.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.07 (EBITDA TTM 14.36b / Interest Expense TTM 2.16b) >= 6 (WARN >= 3)

Altman Z'' 0.92

(A) -0.01 = (Total Current Assets 15.56b - Total Current Liabilities 15.94b) / Total Assets 59.54b

(B) -0.07 = Retained Earnings (Balance) -4.09b / Total Assets 59.54b

(D) -0.07 = Book Value of Equity -4.39b / Total Liabilities 60.77b

Total Rating: 0.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.52

1. Piotroski 7.50pt = 2.50

2. FCF Yield 5.14% = 2.57

3. FCF Margin 10.03% = 2.51

4. Debt/Equity data missing

5. Debt/Ebitda 3.10 = -1.90

6. ROIC - WACC 14.34% = 12.50

7. RoE data missing

8. Rev. Trend 97.87% = 4.89

9. Rev. CAGR 8.22% = 1.03

10. EPS Trend 47.09% = 1.18

11. EPS CAGR 22.48% = 2.25

What is the price of HCA shares?

As of September 13, 2025, the stock is trading at USD 405.13 with a total of 761,184 shares traded.
Over the past week, the price has changed by -3.72%, over one month by +3.80%, over three months by +9.21% and over the past year by +4.27%.

Is HCA Holdings a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, HCA Holdings (NYSE:HCA) is currently (September 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 77.52 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HCA is around 442.77 USD . This means that HCA is currently overvalued and has a potential downside of 9.29%.

Is HCA a buy, sell or hold?

HCA Holdings has received a consensus analysts rating of 4.08. Therefore, it is recommended to buy HCA.

Strong Buy: 13
Buy: 2
Hold: 9
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HCA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	398.6	-1.6%
Analysts Target Price	398.6	-1.6%
ValueRay Target Price	485.7	19.9%

Last update: 2025-09-08 04:40

HCA Fundamental Data Overview

Market Cap USD = 98.46b (98.46b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 939.0m USD (last quarter)
P/E Trailing = 17.6646
P/E Forward = 14.7493
P/S = 1.3543
P/B = 293.44
P/EG = 1.2048
Beta = 1.422
Revenue TTM = 72.70b USD
EBIT TTM = 10.94b USD
EBITDA TTM = 14.36b USD
Long Term Debt = 39.38b USD (from longTermDebt, last quarter)
Short Term Debt = 5.10b USD (from shortTermDebt, last quarter)
Debt = 44.48b USD (Calculated: Short Term 5.10b + Long Term 39.38b)
Net Debt = 45.42b USD (from netDebt column, last quarter)
Enterprise Value = 142.00b USD (98.46b + Debt 44.48b - CCE 939.0m)
Interest Coverage Ratio = 5.07 (Ebit TTM 10.94b / Interest Expense TTM 2.16b)
FCF Yield = 5.14% (FCF TTM 7.29b / Enterprise Value 142.00b)
FCF Margin = 10.03% (FCF TTM 7.29b / Revenue TTM 72.70b)
Net Margin = 8.21% (Net Income TTM 5.97b / Revenue TTM 72.70b)
Gross Margin = 15.24% ((Revenue TTM 72.70b - Cost of Revenue TTM 61.62b) / Revenue TTM)
Tobins Q-Ratio = -32.32 (set to none) (Enterprise Value 142.00b / Book Value Of Equity -4.39b)
Interest Expense / Debt = 1.28% (Interest Expense 568.0m / Debt 44.48b)
Taxrate = 21.89% (1.87b / 8.52b)
NOPAT = 8.54b (EBIT 10.94b * (1 - 21.89%))
Current Ratio = 0.98 (Total Current Assets 15.56b / Total Current Liabilities 15.94b)
Debt / EBITDA = 3.10 (Net Debt 45.42b / EBITDA 14.36b)
Debt / FCF = 6.10 (Debt 44.48b / FCF TTM 7.29b)
Total Stockholder Equity = -3.15b (last 4 quarters mean)
RoA = 10.03% (Net Income 5.97b, Total Assets 59.54b )
RoE = unknown (Net Income TTM 5.97b / Total Stockholder Equity -3.15b)
RoCE = 30.19% (Ebit 10.94b / (Equity -3.15b + L.T.Debt 39.38b))
RoIC = 21.04% (NOPAT 8.54b / Invested Capital 40.62b)
WACC = 6.70% (E(98.46b)/V(142.94b) * Re(9.27%)) + (D(44.48b)/V(142.94b) * Rd(1.28%) * (1-Tc(0.22)))
Shares Correlation 3-Years: -100.00 | Cagr: -1.63%
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.20% ; FCFE base≈6.33b ; Y1≈6.85b ; Y5≈8.49b
Fair Price DCF = 509.1 (DCF Value 119.12b / Shares Outstanding 234.0m; 5y FCF grow 9.20% → 3.0% )
Revenue Correlation: 97.87 | Revenue CAGR: 8.22%
Rev Growth-of-Growth: -2.74
EPS Correlation: 47.09 | EPS CAGR: 22.48%
EPS Growth-of-Growth: 10.10

Additional Sources for HCA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle